Lutetium Lu 177 Vipivotide Tetraxetan

Common brands: Pluvicto, Beizray, Docetaxel, Docivyx, Tylenol Extra Strength

Top reporter: Novartis Pharmaceuticals Corporation

Radioligand Therapeutic Agent [EPC]Corticosteroid [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Microtubule Inhibitor [EPC]Androgen Receptor Inhibitor [EPC]
12,345
Total Reports
12,335
Serious Reports
1,561
Death Reports
30
Reported Reactions
Death Report Ratio: High (12.64%)

Patient Demographics

Male
2,182
Female
20

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Lutetium Lu 177 Vipivotide Tetraxetan.

# Reaction Reports % of Total
1 GENERAL PHYSICAL HEALTH DETERIORATION 5,603
39.4%
2 ILL-DEFINED DISORDER 3,622
25.5%
3 DEATH 1,258
8.8%
4 DISEASE PROGRESSION 322
2.3%
5 MALIGNANT NEOPLASM PROGRESSION 290
2.0%
6 PROSTATIC SPECIFIC ANTIGEN INCREASED 252
1.8%
7 LABORATORY TEST ABNORMAL 251
1.8%
8 FATIGUE 221
1.6%
9 ANAEMIA 179
1.3%
10 ILLNESS 152
1.1%
11 PLATELET COUNT DECREASED 148
1.0%
12 COVID-19 142
1.0%
13 HAEMOGLOBIN DECREASED 136
1.0%
14 HORMONE-REFRACTORY PROSTATE CANCER 133
0.9%
15 THROMBOCYTOPENIA 131
0.9%
16 NAUSEA 130
0.9%
17 PROSTATE CANCER 119
0.8%
18 DRUG INEFFECTIVE 117
0.8%
19 MALAISE 112
0.8%
20 ASTHENIA 111
0.8%
21 DRY MOUTH 106
0.7%
22 SARS-COV-2 TEST POSITIVE 105
0.7%
23 PAIN 89
0.6%
24 METASTASES TO BONE 83
0.6%
25 PROSTATE CANCER METASTATIC 77
0.5%
26 VOMITING 72
0.5%
27 DECREASED APPETITE 71
0.5%
28 PANCYTOPENIA 66
0.5%
29 WEIGHT DECREASED 61
0.4%
30 PNEUMONIA 58
0.4%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.